Safety and Efficacy of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitorin Relapsing Multiple Sclerosis Over 2.5 Years of The Open-Label Extension to a Phase II Trial

Authors
Category Primary study
JournalNeurology
Year 2022
This article has no abstract
Epistemonikos ID: a1f91240868c297003a64ec5ef990d4c86dce062
First added on: Feb 14, 2025